Angiochem presents results of Phase 2 research with ANG1005 in breast cancer individuals with brain metastases Angiochem, a clinical stage biotechnology business developing medications that are uniquely with the capacity of crossing the blood-human brain barrier , announced that the complete analysis outcomes of a Phase 2 clinical research with ANG1005, a novel paclitaxel-peptide medication conjugate, in breast malignancy patients with brain metastasis were presented today at the 2013 AACR-NCI-EORTC Molecular Targets and Tumor Therapeutics Conference cialis here .

her

Phase 1 and Phase 2 clinical research demonstrated promising symptoms of both CNS and peripheral anti-tumor activity of ANG1005 in individuals with brain metastases including breast malignancy patients. Predicated on these data, Angiochem also announced today that the company has initiated a Stage 2 scientific trial with ANG1005 designed to confirm this anti-tumor activity as a potential fresh approach to treating HER2+ breast tumor.D., President and CEO of Angiochem. ‘Effective management of patients with human brain metastases is still a significant clinical challenge. By actively penetrating the blood-mind barrier and cancers cells through LRP-1 receptor, ANG1005 elicits both CNS and peripheral tumor responses and a potential brand-new treatment option for this difficult to take care of patient population.’ The info to be offered at ASCO includes results from a Phase 1 and initial Phase 2 clinical research of ANG1005 in HER2+ and HER2 – breasts cancer patients and solid tumors with brain metastases where promising symptoms of anti-tumor activity had been observed both in CNS and at the periphery.